The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
Open accessAbstract
Purpose: The study objective was to determine the proportion of patients with hepatocellular carcinoma (HCC) treated with the combination of bevacizumab (B) and erlotinib (E) who were alive and progression free at 16 weeks (16-week progression-free survival [PFS 16]) of continuous therapy. Secondary objectives included response rate, median PFS, survival, and toxicity. Patients and Methods: Patients who had advanced HCC that was not amenable to surgical or regional therapies, up to one prior systemic treatment; Childs-Pugh score A or B liver function; Eastern Cooperative Oncology Group performance status 0, 1, or 2 received B 10 mg/kg every 14 days and E 150 mg orally daily, continuously, for 28-day cycles. Tumor response was evaluated every 2 cycles by using Response Evaluation Criteria in Solid Tumors Group criteria. A total of 40 patients were treated. Results: The primary end point of PFS 16 was 62.5%. Ten patients achieved a partial response for a confirmed overall response rate (intent-to-treat) of 25%. The median PFS event was 39 weeks (95% CI, 26 to 45 weeks; 9.0 months), and the median overall survival was 68 weeks (95% CI, 48 to 78 weeks; 15.65 months). Grades 3 to 4 drug-related toxicity included fatigue (n = 8; 20%), hypertension (n = 6; 15%), diarrhea (n = 4; 10%) elevated transaminases (n = 4; 10%), gastrointestinal hemorrhage (n = 5; 12.5%), wound infection (n = 2; 5%) thrombocytopenia (n = 1; 2.5%), and proteinuria, hyperbilirubinemia, back pain, hyperkalemia, and anorexia (n = 1 each). Conclusion: The combination of B + E in patients who had advanced HCC showed significant, clinically meaningful antitumor activity. B + E warrant additional evaluation in randomized controlled trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
Garcia-Tsao, G., Sanyal, A. J., Grace, N. D., & Carey, W. (2007) · Hepatology · doi:10.1002/hep.21907 · Cited by 1,722
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
(2011) · Hepatogastroenterology · doi:10.5754/hge11453 · Cited by 1,254
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
(1998) · Hepatology · doi:10.1002/hep.510280322 · Cited by 1,238
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
Yeo, W., Mok, T. S., Zee, B., Leung, T. W. T., Lai, P. B. S., Lau, W. Y., Koh, J., Mo, F. K. F., Yu, S. C. H., Chan, A. T., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji315 · Cited by 590
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
Poon, R. T.-P., Fan, S.-T., & Wong, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1207 · Cited by 587
(2000) · Hepatology · doi:10.1053/he.2000.5628 · Cited by 521
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462
Chang, Y. S., Adnane, J., Trail, P. A., Levy, J., Henderson, A., Xue, D., Bortolon, E., Ichetovkin, M., Chen, C., McNabola, A., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0393-4 · Cited by 459
Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
Simonetti, R. G., Liberati, A., Angiolini, C., & Pagliaro, L. (1997) · Annals of Oncology · doi:10.1023/a:1008285123736 · Cited by 380
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?
Nair, S., Mason, A., Eason, J., Loss, G., & Perrillo, R. P. (2002) · Hepatology · doi:10.1053/jhep.2002.33713 · Cited by 348
Schiffer, E., Housset, C., Cacheux, W., Wendum, D., Desbois‐Mouthon, C., Rey, C., Clergue, F., Poupon, R., Barbu, V., & Rosmorduc, O. (2005) · Hepatology · doi:10.1002/hep.20538 · Cited by 340
Schmitz, K. J., Wohlschlaeger, J., Lang, H., Sotiropoulos, G. C., Malago, M., Steveling, K., Reis, H., Cicinnati, V. R., Schmid, K. W., & Baba, H. A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.08.018 · Cited by 309
Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Hicklin, D. J., Wu, Y., Yanase, K., Namisaki, T., Yamazaki, M., et al. (2003) · Gut · doi:10.1136/gut.52.9.1347 · Cited by 307
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Thomas, M. B., Chadha, R., Glover, K., Wang, X., Morris, J., Brown, T., Rashid, A., Dancey, J., & Abbruzzese, J. L. (2007) · Cancer · doi:10.1002/cncr.22886 · Cited by 306
Self-citationNovo, E., Cannito, S., Zamara, E., di Bonzo, L. V., Caligiuri, A., Cravanzola, C., Compagnone, A., Colombatto, S., Marra, F., Pinzani, M., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060887 · Cited by 220
Chao, Y., Li, C.-P., Chau, G.-Y., Chen, C.-P., King, K.-L., Lui, W.-Y., Yen, S.-H., Chang, F.-Y., Chan, W.-K., & Lee, S.-D. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.10.002 · Cited by 209
on behalf of the Membership of the International Cancer Imaging Society, Husband, J. E., Schwartz, L. H., Spencer, J., Ollivier, L., King, D. M., Johnson, R., & Reznek, R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601843 · Cited by 161
Ng, K. K., Poon, R. T. P., Lo, C., Yuen, J. H. F., Tso, W. K., & Fan, S.-T. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0276-y · Cited by 156
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma†
Ho, J. W., Pang, R. W. C., Lau, C. P.-Y., Sun, C. K.-W., Yu, W. C., Fan, S. T., & Poon, R. T. P. (2006) · Hepatology · doi:10.1002/hep.21353 · Cited by 136
Wada, H., Nagano, H., Yamamoto, H., Yang, Y., Kondo, M., Ota, H., Nakamura, M., Yoshioka, S., Kato, H., Damdinsuren, B., et al. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01243.x · Cited by 130
Yao, D., Wu, X., Zhu, Y. M., Shi, G.-S., Dong, Z., Yao, D.-B., Wu, W., Qiu, L., & Meng, X. (2005) · PubMed · Cited by 128
Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer
Sandler, A. B., Johnson, D. H., & Herbst, R. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040023 · Cited by 125
Poon, R. T. P., Lau, C. P.-Y., Pang, R. W. C., Ng, K. K., Yuen, J. H. F., & Fan, S. T. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9366-z · Cited by 117
Chronic Viral Hepatitis and Hepatocellular Carcinoma
Barazani, Y., Hiatt, J. R., Tong, M. J., et al. (2007) · World Journal of Surgery · doi:10.1007/s00268-007-9041-3 · Cited by 98
Is There Room for Improvement in Adverse Event Reporting in the Era of Targeted Therapies?
Edgerly, M., & Fojo, T. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm324 · Cited by 65
Cui, J. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i10.1533 · Cited by 53
Angiogenesis in chronic liver disease
Amarapurkar, A. D., Amarapurkar, D. N., Vibhav, & Patel, N. D. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31924-6 · Cited by 53
Genescà, J., González, A., Catalan, R., Segura, R., Martinez, M., Esteban, R., Groszmann, R. J., & Guàrdia, J. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026618904493 · Cited by 48
Serum endostatin levels in patients with hepatocellular carcinoma
Yamagata, M., Shiratori, Y., Dan, Y., Shiina, S., Takayama, T., Makuuchi, M., & Omata, M. (2000) · Annals of Oncology · doi:10.1023/a:1008318526938 · Cited by 26
Angiogenic Factor Expression in Hepatic Cirrhosis
Giatromanolaki, A. N., Kotsiou, S., Koukourakis, M. I., & Sivridis, E. (2007) · Mediators of Inflammation · doi:10.1155/2007/67187 · Cited by 20
Molecular Genetic Alterations in Primary Hepatocellular Neoplasms
Grisham, J. W. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-125-1_14 · Cited by 16
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Bevacizumab has been evaluated as single agent [336], or in combination with erlotinib [337] or chemotherapy [338].”
BackgroundEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
Metadata
- Authors
- Thomas, M. B., Morris, J. S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E., Kaseb, A., Glover, K., Davila, M., & Abbruzzese, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-20
- Volume
- 27
- Issue
- 6
- Pages
- 843-850
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166805191
- Cited by
- 334
- References
- 41
- FWCI
- 33.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.